X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds from the funding will be used to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD).
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 26, 2023
Details:
Through the merger, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs including DPI-125, being studied as a potential novel treatment for opioid use disorder.
Lead Product(s): DPI-125
Therapeutic Area: Psychiatry/Psychology Product Name: DPI-125
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: DMK Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 25, 2023
Details:
Through the merger, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs including DPI-125, being studied as a potential novel treatment for OUD.
Lead Product(s): DPI-125
Therapeutic Area: Psychiatry/Psychology Product Name: DPI-125
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: DMK Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 27, 2023
Details:
Tempol (MMB-02) capsule, is a redox cycling nitroxide in development for the treatment of patients with COVID-19, was the subject of a Phase 2/3 clinical trial which has been halted.
Lead Product(s): Tempol
Therapeutic Area: Infections and Infectious Diseases Product Name: Tempol
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
This trial did not meet its primary endpoint, but we are exploring the possibility that vaccinations and the less virulent variants (Omicron) during the trial period may have obscured an effect of Tempol (MMB-02).
Lead Product(s): Tempol
Therapeutic Area: Infections and Infectious Diseases Product Name: Tempol
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Tempol (MMB-02) is a redox cycling nitroxide that promotes the metabolism of many reactive oxygen species and improves nitric oxide bioavailability. It has been studied extensively in animal models of oxidative stress and inflammation.
Lead Product(s): Tempol
Therapeutic Area: Infections and Infectious Diseases Product Name: Tempol
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The results of published study suggesting that MMB-02 (tempol) Capsule has strong, broad in-vitro anti-cytokine activity. Suppression of inflammatory cytokines with an antioxidant may be a beneficial treatment strategy in early COVID-19 infection.
Lead Product(s): Tempol
Therapeutic Area: Infections and Infectious Diseases Product Name: Tempol
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stanford University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
ZIMHI represents a new tool for patients by combining an intuitive, compact, and simple to use intramuscular device with a high dose of naloxone. Successfully treating overdoses involving fentanyl often requires multiple doses of lower-dose or intranasal naloxone products.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Zimhi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: US WorldMeds
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus, resulted in a significant decrease in inflammation in the lungs of animals treated with Tempol (MBM-02), a novel antioxidant, compared to controls.
Lead Product(s): Tempol
Therapeutic Area: Infections and Infectious Diseases Product Name: Tempol
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galveston National Laboratory
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Data Safety Monitoring Board met to evaluate interim clinical and safety data and clears, from the first planned interim analysis Phase 2/3 study to continue for Tempol, for the treatment of COVID-19.
Lead Product(s): Tempol
Therapeutic Area: Infections and Infectious Diseases Product Name: Tempol
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
